Brazilian Journal of Implantology and Health Sciences · Nov 3, 2026
EARLY BIOMARKERS AND PREVENTION AS A NEW PARADIGM IN ALZHEIMER DISEASE AND PARKINSON DISEASE: A STRUCTURED NARRATIVE REVIEW
By Amorim ARJ, de Carvalho JMJ, Amorim RJ et al.
OBJECTIVE: To synthesize evidence on biomarkers in DA and DP, differentiate diagnostic from preventive roles, quantify economic and equity impacts, and structure guidelines for future meta-analyses. METHODS: A structured narrative review (March 2026) in the PubMed and Embase databases. A dual PICO strategy, predefined eligibility criteria, and bias assessment using QUADAS-2, ROBINS-I, and RoB 2 were applied, with evidence graded using the GRADE system. RESULTS: Eleven primary studies were analyzed. In DA, p-tau217 achieved an accuracy of 85–91%; molecular changes precede diagnosis by 18 years. In DP, the sensitivity of $\alpha$-synuclein SAA exceeded 0.91. In the therapeutic field, lecanemab had an ICER of US$ 981.000/QALY, exceeding the cost-effectiveness threshold (US$ 150.000). Ethnic disparities were detected: African Americans have systematically lower p-tau181 and 7–12% lower amyloid PET positivity, despite higher rates of clinical dementia. CONCLUSIONS: Precision neurology is operationally feasible for diagnosis, but its consolidation as preventive medicine requires validation in diverse populations and economic sustainability. Equitable implementation requires global standardization of platforms and calibration of biological cutoffs to mitigate diagnostic disparities.
doi.org/10.36557/2674-8169.2026v8n11p190-213Open accessBiomarkers